Jefferies maintains Azenta at Buy, raises price target to $52 from $44

Jefferies reaffirmed its Buy rating on Azenta and increased its price target to $52 from $44, representing an 18.2% increase. The new target suggests a 28.5% upside from the Nov 10 closing price of $40.48, according to the firm.

Original reporting
Published Nov 11, 2026, 8:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jefferies maintains Azenta at Buy, raises price target to $52 from $44 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The new target suggests a 28.5% upside from the recent close, likely prompting buying interest.

02

Market read

A fresh analyst target raise provides a short‑term catalyst for AZN.

03

What to watch

Potential supply‑chain constraints or regulatory delays not addressed in the note.

Relevance 6/10Novelty 6/10Timing: today

Background

Azenta (AZN) is a biotech services firm; analyst upgrades can move its price.

Market effects

May boost sentiment in the life‑science equipment sector.

Limited to U.S. and global investors tracking analyst upgrades.

Low; impact confined to Azenta and its peers.

Counterpoint

The target raise could be premature if recent earnings missed expectations.

Key entities

  • Jefferies

    Equity research firm that issued the rating upgrade.

  • Azenta

    Biotech services provider.

Related articles

$AZTAHigh

Why Azenta Stock Crushed it on Wednesday

Azenta (AZTA) stock surged 21% after reporting Q4 2026 revenue of $167M, up 5% YoY, and adjusted earnings of $0.28 per share, exceeding estimates. The company guided FY2027 revenue to $648M-$660M with margin expansion. Azenta focuses on automated sample storage for healthcare.

$AZTAHigh

Azenta (AZTA) Q4 2026 Earnings Call Transcript

Azenta (AZTA) reported Q4 2026 revenue slightly better than expected, with double-digit growth in Sample Repository Services and Consumables & Instruments. The company aims for profitable revenue growth in 2027, with initiatives in commercial expansion and new product launches. Fiscal 2026 saw 2% organic revenue growth and an adjusted EBITDA margin of 9.4%.

$AZTAMedAI 8/10

What Azenta (AZTA) Said on Its Q4 Earnings Call

Azenta (AZTA) reported Q4 revenue growth of 9% in Sample Management Solutions and flat revenue in Multiomics. The company expects 3-4% organic revenue growth in Q1 and improved free cash flow by 25% in fiscal 2026. Automated Stores faced challenges but is expected to return to modest growth. Azenta made acquisitions in gene synthesis and plans restructuring for cost savings.